Logo

Empire Genomics Lands CE Mark for Several Products

Dec 17, 2015 | staff reporter

NEW YORK (GenomeWeb) – Molecular diagnostics firm Empire Genomics today announced that it has received CE Marking for several of its products including fluorescent in situ hybridization probes and karyotyping media.

Landing the CE Mark "will please our world distributors and will go a long way in accelerating sales in Europe," Empire VP of International Business Development Reza Mazaheri said in a statement.

The firm said cytogenetic media, immunohistochemistry products, and fish probes were among the products to receive the CE Mark. Empire offers several molecular diagnostics products and services including FISH, genotyping, next-generation sequencing, and gene expression.

In January, Buffalo, New York-based Empire bought Canadian molecular diagnostics firm ID Labs.

Filed under

Regulatory News & FDA Approvals
Molecular Diagnostics
CE mark
FISH
molecular cytogenetics
Empire Genomics
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.